ALXN
Alexion Pharmaceuticals Inc
ALXN
ALXN
Delisted
ALXN was delisted on the 20th of July, 2021.
559 hedge funds and large institutions have $26B invested in Alexion Pharmaceuticals Inc in 2017 Q2 according to their latest regulatory filings, with 72 funds opening new positions, 254 increasing their positions, 178 reducing their positions, and 68 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
559
Holders Change
-2
Holders Change %
-0.36%
% of All Funds
13.96%
Holding in Top 10
19
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+11.76%
% of All Funds
0.47%
New
72
Increased
254
Reduced
178
Closed
68
Calls
$675M
Puts
$459M
Net Calls
+$215M
Net Calls Change
+$211M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$2.78B |
| 2 |
Goldman Sachs
New York
|
$584M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
$1.04B |
| 4 |
BlackRock
New York
|
$2.42B |
| 5 |
TP
Third Point
New York
|
$152M |
Top Sellers
| 1 |
Jennison Associates
New York
|
$79.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
$2.6B |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
$1.75M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
$68.8M |
| 5 |
JPMorgan Chase & Co
New York
|
$160M |
